ATS: Upfront Combination Versus Monotherapy in Pulmonary Arterial Hypertension (PAH): Can Advanced Risk Stratification Tell Us the Real Benefit?

J.V. Scott, L.C. Lohmueller , C.G. Garnett , M.K. Kanwar , R.L. Benza. A105 GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH / Poster Discussion Session / American Thoracic Society 2019;199:A7346 Rationale: The Registry to Evaluate Early and Long-Term PAH Disease Management recently updated their linear multivariable risk-stratification tool (REVEAL 2.0). Our ongoing study aims […]

The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.

Kanwar M, Raina A, Lohmueller L, Kraisangka J, Benza R. Current Hypertension Reports. 2019 Apr 25;21(6):45. doi: 10.1007/s11906-019-0950-y. Review. PMID: 31025123 Abstract PURPOSE OF REVIEW: Pulmonary arterial hypertension (PAH) is a chronic, progressive, and incurable disease with significant morbidity and mortality. Despite increasingly available treatment options, PAH patients continue to experience disease progression and increased […]